E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Crohn's Disease (active moderate to severe) |
|
E.1.1.1 | Medical condition in easily understood language |
Crohn's Disease (active moderate to severe) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011401 |
E.1.2 | Term | Crohn's disease |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of this study are to demonstrate clinical activity of PF-04236921 that will induce a clinical response and remission in subjects with Crohn’s Disease (CD) via the Crohn’s Disease Activity Index (CDAI) and to select dose(s) for future clinical studies. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives include:
• Evaluate safety, tolerability, and immunogenicty of PF-04236921.
• Characterize population pharmacokinetics (PK) of PF-04236921 in subjects with CD
Exploratory Objectives
• Explore the relationship between PK/PD and CDAI score and biomarkers.
• Characterize PD and other biomarkers
• Assess health outcome measures in IBDQ and EQ 5D™.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
3. Male and/or female subjects between the ages of ≥18 and ≤75 years.
4. Subjects must have failed or are intolerant to anti TNFs
• Relapsed after at least 1 anti TNF.
• Primary non-responder to at least 1 anti TNF (maximum 50% of subjects).
• Intolerant to at least 1 anti TNF
• Other – Discontinued at least 1 anti TNF regimen for other reasons.
(Note: the anti TNF failure type is one of the stratification factors in this study. Primary non responders will be limited up to 50% of total enrollment by stratification. Intolerant subjects are those not meeting one of the prior 2 categories)
5. Active moderate to severe ileal (terminal ileum), ileocolic, or colonic CD (CDAI scores ≥220 to ≤450), despite use of mesalamine (5 ASAs), and/or immunosupressants (AZA, 6 MP, and MTX) (May continue use of 5 ASAs, AZA, MTX and 6 MP in this trial; dose must be stable 4 weeks prior to screening visit).
(Note: the background immunosuppressant therapy type (AZA, 6MP, MTX or none) is another stratification factor in this study.)
6. hsCRP ≥5 mg/L.
7. Ulcerations demonstrated by colonoscopy performed during screening as defined by SES CD assessment (Colonoscopy to be completed after signing ICD and verification of eligible lab values).
8. All women of childbearing potential (WOCBP) must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at baseline and throughout the duration of the study.
• WOCBP are defined as women who are biologically capable of becoming pregnant, including women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
• Women of non childbearing potential (WONCBP) are defined as either postmenopausal (history of amenorrhea for ≥52 weeks and confirmation by FSH level) or who are surgically sterile, such as after hysterectomy, bilateral oophorectomy, or tubal ligation (procedure performed ≥52 weeks before screening). This information must be documented in the subject's source documents.
• WONCBP do not require a serum and urine pregnancy test.
9. WOCBP who have sexual intercourse with a non-surgically sterilized male must agree and commit to the use of the following highly effective methods of contraception for the duration of the study (defined as the time of the signing of the ICF through the conclusion of subject participation or for approximately 9 months from the last dose of investigational product for any subject who discontinues early from the study). Female subjects who meet the criteria will be advised to continue a highly effective method of birth control for an additional 40 weeks at the conclusion of study participation due to the possible presence of low levels of investigational product. Contraceptive methods considered acceptable for use in this study include:
• Established use [≥2 months prior to the screening visit] of oral, injected, transdermal or implanted hormonal methods of contraception.
• Hormonal contraception must be accompanied by the use of a physical barrier method such as use of a spermicidal condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
• Double barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. A female condom and a male condom should not be used together as friction between the two can result in either, or both, product(s) failing.
• An intrauterine device or system.
10. All men (unless surgically sterile, as defined below) who have sexual intercourse with a WOCBP must agree and commit to use a highly effective method of contraception as described under WOCBP for the duration of the study (defined as the time of the signing of the ICF through the conclusion of subject participation or for approximately 9 months from the last dose of investigational product for any subject who discontinues early from the study). Male subjects who meet the criteria will be advised to continue a highly effective method of birth control for an additional 40 weeks at the conclusion of study participation due to the possible presence of low levels of investigational product. Highly effective methods of contraception include properly used spermicidal condom.
• To be considered surgically sterilized, a male partner must have had a vasectomy at least 24 weeks or bi-lateral orchiectomy >30 days before screening. |
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following will not be included in the study:
Medical History
1. Pregnant or breastfeeding women.
2. CD with active fistulae or abscess. Subjects with a prior history of fistulae or abdominal or perineal abscess or have not completed the usual CT/MR work up for extent of disease must have CT or MR enterography during screening to exclude active fistulae or abdominal or perineal abscess prior to study entry. MR enterography may be preferred since it does not have radiation exposure.
3. Subjects who had a colectomy with ileorectal anastomosis, or multiple small bowel resections resulting in clinically relevant short bowel syndrome with clinically significant malabsorption or need for TPN, in the opinion of the Investigator.
4. Previous bowel surgery resulting in a stoma or surgical bowel resection within the past 3 months.
5. History of diverticulitis or symptomatic diverticulosis.
6. Pre existing demyelinating disorder such as multiple sclerosis, new onset seizures, unexplained sensory, motor, or cognitive, behavioral or neurological deficits.
7. Known history of HIV based on documented history with positive serological test, or positive HIV serologic test at screening, tested at the site’s local lab. (Note: a documented negative HIV test within 12 months of screening is acceptable and does not need to be repeated).
8. Significant concurrent medical conditions at the time of screening or baseline visit, including, but not limited to, the following:
• Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI, endocrine, pulmonary, immunologic [eg, Felty syndrome], or local active infection/infectious illness) that, in the investigator’s judgment, will substantially increase the risk to the subject if he or she participates in the study.
• Cancer or history of cancer or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence).
• Class III or IV congestive heart failure as defined by the New York Heart Association.
• Acute coronary syndrome (eg, myocardial infarction, unstable angina pectoris) and any history of significant cerebrovascular disease within 24 weeks before screening.
9. Any major elective surgery scheduled to occur during the study.
10. Presence of a transplanted organ.
11. Prior evidence of liver injury or toxicity due to methotrexate.
Physical and Laboratory Findings
12. Abnormal findings on the a chest x ray film, performed routinely before initiating a new biologic therapy, such as presence of tuberculosis (TB), general infections, heart failure, or malignancy. (Chest x ray examination may be performed up to 12 weeks prior to study entry. Documentation of the official reading must be located and available in the source documentation).
13. Any history or current evidence of latent or active tuberculosis infection, evidence of prior or currently active tuberculosis by chest radiography, residing with or frequent close contact with individual(s) with active tuberculosis. Subjects who have a positive Mantoux (PPD) tuberculin skin test or a positive Interferon Gamma Release Assay performed locally (the following are acceptable assays: QuantiFERON® TB Gold test (QFT G), QuantiFERON® TB Gold In Tube test (QFT GIT) and T SPOT® TB test) during screening or within 12 weeks prior to randomization.
• A positive Mantoux tuberculin skin test is defined as ≥5 mm of induration (or as defined by country specific or local standards) at 48 72 hours without consideration of prior Bacillus Calmette-Guérin (BCG) vaccination. Documentation of the dose and product used as well as the official test reading must be obtained and available in the subject's study file.
• An IGRA is preferred for subjects with a prior Bacillus Calmette Guérin (BCG) vaccination (to be tested by the site’s local lab). Documentation of IGRA product used and the test result must be in the subject’s source documentation.
Please refer to the protocol for full list of exclusion criteria |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The CDAI 70 response rate at Week 8 or Week 12 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Percent of subjects with a CDAI remission (CDAI <150), CDAI 70 and CDAI 100 responses Weeks 2 through 12 (Day 14 to Day 84).
• Mean change from baseline for CDAI score Weeks 2 through 12 (Day 14 to Day 84).
• Safety and tolerability of PF-04236921 dose levels versus placebo: the frequency of on treatment adverse events, withdrawals due to adverse events, and SAEs will be reported. Any subject who receives at least 1 dose of investigational product will be included in the evaluation for safety.
• Percent of subjects that develop ADAs and NAbs, if observed, measured at baseline, and Weeks 4, 8, 12, 16, 24, 32 and 40 will be reported.
• Serum concentrations of PF-04236921 measured at baseline and bi weekly up to Week 12 and monthly through Week 40 will be reported.
Exploratory Endpoints
• Mean change from baseline for PD biomarkers (total and free IL 6, hsCRP) measured bi weekly up to Week 12 and monthly through Week 40 will be reported. Fecal calprotectin will be measured monthly up to Week 12 and will be reported.
• Health Outcomes (IBDQ, EQ 5D) will be measured monthly through Week 12.
• Non specific disease biomarkers (fibrinogen and SAA) will be measured monthly with routine laboratory tests up to Week 12.
• The Prometheus IBD biomarkers will be evaluated at baseline.
• PK/PD modeling of dose and dose response relationships of the PD and exploratory biomarkers may be conducted |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The timepoints are define with the seconday endpoints |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability & Immunogenicity |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Brazil |
Canada |
Denmark |
Greece |
Ireland |
Israel |
Italy |
New Zealand |
Romania |
Switzerland |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |